...KRAS mutations are associated with poor response. Determining the presence of EGFR/KRAS mutations in tumor DNA shed into...
...KRAS in tumor tissue is being analyzed when archived material is available.,Enrollment into the intermittent cohort is c...
...KRAS 2 exons were amplified and sequenced.,Tumor samples were collected from 65/88 eligible participants. 50 (81%) were ...
...KRAS mut than in KRAS-wild type (WT) tumors (2.26 vs 2.77; Mann-Whitney U test, p=0.022). A logistic regression model wi...
...KRAS mutations (14/92; 15%) had shorter OS and PFS vs wild-type KRAS (78/92; 85%); HR 1.73 and 1.37, respectively (ns). ...
...KRAS mutation (pancreas, PD), 1 of 8 had EGFR amplification by FISH (heavily pre-treated breast, SD). Additional planned...
...KRAS mutations (codon 12, 13) were detected in 9/31 (29%) pts. Disease control at 8 weeks was seen in 41% of pts with KR...
...KRAS in relation to outcome of treatment. No significant financial relationships to disclose.
...Kras mutations using different biological techniques, and mutations of the p53 gene (exons 5 to 9) by sequence analysis....
...KRAS mutations. The presence of a KRAS mutation contraindicates EGFR TKI therapy indicating other agents, or investigati...
联系地址
山东省济南市章丘区文博路2号
齐鲁师范学院 genelibs生信实验室
山东省济南市高新区舜华路750号
大学科技园北区F座4单元2楼
电话： 0531-88819269
版权所有 © 2025.Genelibs 济南弘晖生物技术有限公司 鲁ICP备20007159号-2
